Search

Human respiratory syncytial virus (HRSV) is one of the main drivers of lower respiratory tract illness in infants and young children worldwide. There are no licensed vaccines for HRSV available. Exosomes are cell-derived extracellular nanovesicles containing various biomolecules for intracellular communication. Exosomes secreted by antigen presenting cells such as dendritic cells can elicit immune responses by carrying MHC-I with antigenic peptide complex and other co-stimulating factors. Therefore, exosomes have emerged as potential vaccines to prevent viral infections or to treat cancers. Our prior work has demonstrated that a PDMS microfluidic culture chip device can be used to generate dendritic cell-derived tumor antigenic exosomes, with the capacity to activate tumor-specific CD8+ T cells. Herein, we further extended the work to surface engineer dendritic cell-derived exosomes with antigenic peptides from RSV (M187–195 and NS161–75). A mouse model of RSV infection was used to define the immunogenicity of surface engineered exosomes for activating virus-specific immune responses in vitro and in vivo. In vitro assays demonstrated that surface engineered exosomes successfully carried the engineered peptides of interest and had the capacity to elicit IFNγ production by activated, virus-specific CD8+ T cells. However, vaccination with engineered exosomes did not prime an in vivo activation of antigen-specific CD8+ T cell response, although surface engineered exosomes exhibit the safe administration. Additional experiments are necessary to optimize the potency of surface engineered exosomes as a vaccine platform for the prevention of viral infections such as RSV.

e19407 Background: The purpose of this study was to evaluate the impact of a continuous improvement process aimed at reducing time to treatment on minimizing the number of days spent to complete pre-treatment visits and the associated costs for patients with non-metastatic breast cancer. Methods: System-wide initiatives were implemented in 2015 to minimize time to treatment initiation (TTI), by incorporating lean process strategies and enhanced coordination. Patient and treatment information was obtained through an IRB-approved registry for the years 2015 and 2018. Average number of days spent to complete visits, TTI, and associated patient costs including driving expenses, parking, food, childcare, and lost wages were calculated and compared between the years 2015 and 2018. Results: In 2015, the median TTI was 43.5 days and the average number of separate days spent to attend multidisciplinary visits prior to first treatment was 1.86. These were reduced to 29 days and 1.52 visits, respectively, in 2018 (p < 0.0001 for both). When evaluating treatment visits by surgical procedure, the average number of visits was reduced regardless of surgical procedure. The average number of visits was highest for patients undergoing mastectomy with reconstruction (2.34 in 2015, reduced to 1.65 in 2018, p < 0.0001). A single visit to complete treatment planning was associated with patient costs of $249 as compared with multiple trips costing $491 for 2 visits and up to $1,226 for 5 visits. Conclusions: In breast cancer patients, implementing a continuous improvement process to reduce time to treatment was associated with fewer visits required prior to treatment initiation, resulting in lower patient costs.

3D printing services are an increasingly popular offering in many academic library makerspaces. However, failed prints, and simply the printing process itself, can generate substantial waste. Throu...

Extracellular vesicles (EVs), particularly nano-sized small EV exosomes, are emerging biomarker sources. However, due to heterogeneous populations secreted from diverse cell types, mapping exosome multi-omic molecular information specifically to their pathogenesis origin for cancer biomarker identification is still extraordinarily challenging. Herein, we introduced a novel 3D-structured nanographene immunomagnetic particles (NanoPoms) with unique flower pom-poms morphology and photo-click chemistry for specific marker-defined capture and release of intact exosome. This specific exosome isolation approach leads to the expanded identification of targetable cancer biomarkers with enhanced specificity and sensitivity, as demonstrated by multi-omic exosome analysis of bladder cancer patient tissue fluids using the next generation sequencing of somatic DNA mutations, miRNAs, and the global proteome. The NanoPoms prepared exosomes also exhibit distinctive in vivo biodistribution patterns, highlighting the highly viable and integral quality. The developed method is simple and straightforward, which is applicable to nearly all types of biological fluids and amenable for enrichment, scale up, and high-throughput exosome isolation.

In recent years, cancer immunotherapy has been observed in numerous preclinical and clinical studies for showing benefits. However, due to the unpredictable outcomes and low response rates, novel targeting delivery approaches and modulators are needed for being effective to more broader patient populations and cancer types. Compared to synthetic biomaterials, extracellular vesicles (EVs) specifically open a new avenue for improving the efficacy of cancer immunotherapy by offering targeted and site-specific immunity modulation. In this review, the molecular understanding of EV cargos and surface receptors, which underpin cell targeting specificity and precisely modulating immunogenicity, are discussed. Unique properties of EVs are reviewed in terms of their surface markers, intravesicular contents, intrinsic immunity modulatory functions, and pharmacodynamic behavior in vivo with tumor tissue models, highlighting key indications of improved precision cancer immunotherapy. Novel molecular engineered strategies for reprogramming and directing cancer immunotherapeutics, and their unique challenges are also discussed to illuminate EV's future potential as a cancer immunotherapeutic biomaterial.

Extracellular vesicles (EVs), particularly exosomes, are emerging biomarker sources. However, due to heterogeneous populations secreted from diverse cell types, mapping EV multi-omic molecular information specifically to their pathogenesis origin for cancer biomarker identification is still extraordinary challenging. Herein, we introduced a novel 3D-structured nanographene immunomagnetic particles (NanoPoms) with unique flower pom-poms morphology and photo-click chemistry for specific marker-defined capture and release of intact small EVs. This specific EV isolation approach leads to the expanded identification of targetable cancer biomarkers with enhanced specificity and sensitivity, as demonstrated by multi-omic EV analysis of bladder cancer patient tissue fluids using the next generation sequencing of somatic DNA mutations, miRNAs, and the global proteome. The NanoPoms prepared sEVs also exhibit distinctive in vivo biodistribution patterns, highlighting the highly viable and integral quality. The developed method is simple and straightforward, and is applicable to nearly all types of biological fluids and amenable for scale up and high-throughput EV isolation.

Breast cancer treatment often requires multi-disciplinary evaluation, which can require multiple visits, delaying time to treatment initiation (TTI). The present analysis evaluated the impact of system-wide initiatives to reduce TTI by evaluating TTI for patients completing treatment evaluation in a single visit compared with those having multiple visits. The results demonstrated that patients who completed multi-disciplinary evaluation in a single visit had a reduced median TTI (27 vs 32 days, P = .002), which was seen for patients undergoing initial surgery (28.0 vs 33.5 days, P = .01) as well as for those undergoing neoadjuvant systemic therapy (22.5 vs 29 days, P = .05).

Transforming Growth Factor-β (TGF-β) has been implicated in a variety of cellular functions, including control of cell cycle, cell proliferation, extracellular matrix formation, and even stem cell differentiation. TGF-β is also a contributor for combinatorial cellular responses, including cellular senescence, cellular apoptosis, and tumor progression. As a result, spatial and temporal control of TGF-β delivery has the potential to lead to greater control over cell signaling while minimizing the potential for undesirable off-target effects. We recently reported magnetically triggered release of active TGF-β from TGF-β Latent Complex conjugated to high-specific absorption rate (SAR) magnetic nanoparticles via magnetic hyperthermia; here we redirected our approach to spin vortex discs. Planar, gold-coated Permalloy (Ni80Fe20) microdiscs (∼2.0 µm diameter, 70 nm thick) were fabricated via standard lithography techniques and thin-film deposition. The discs were then bioconjugated with latent TGF-β via gold-thiol conjugation chemistry, and shear stress on the attached latent TGF-β was induced via magnetic actuation of the discs. This magnetic actuation was achieved via application of a spatially uniform dual pulsating magnetic field (∼1 mT) using two perpendicular pairs of Helmholtz coils at a frequency of 20 Hz for 1 hour. Preliminary results of the bioconjugated discs shown here indicate a significant increase in the release of active TGF-β compared to the baseline passive release. Further studies will focus on investigating non-invasive remote activation and direction of TGF-β by a magnetic field, as well as investigating the potential of expanding this work to other growth factors that exist in latent and active forms.

The excellent rheological property has legitimated the suitability of starch hydrogel for extrusion-based 3D printing. However, the inability to promote cell attachment and migration has precluded the non-modified starch hydrogel from direct applications in the biomedical field. Herein, we develop a novel 3D printable nanocomposite starch hydrogel with highly enhanced biocompatibility for promoting 3D cell growth, by formulating with gelatin nanoparticles and collagen. The rheological evaluation reveals the shear-thinning and thixotropic properties of the starch-based hydrogel, as well as the combinatorial effect of collagen and gelatin nanoparticles on maintaining the printability and 3D shape fidelity. The homogeneous microporous structure with abundant collagen fibers and gelatin nanoparticles interlaced and supplies rich attachment sites for cell growth. Corroborated by the cell metabolic activity study, the multiplied proliferation rate of cells on the 3D printed nanocomposite starch hydrogel scaffold confirms the remarkable enhancement of biological function of developed starch hydrogel. Hence, the developed nanocomposite starch hydrogel serves as a highly desirable bio-ink for advancing 3D tissue engineering.

Conjugation of latent growth factors to superparamagnetic iron oxide nanoparticles (SPIONs) is potentially useful for magnetically triggered release of bioactive macromolecules. Thus, the goal of this work was to trigger the release of active Transforming Growth-Factor Beta (TGF-&beta, ) via magnetic hyperthermia by binding SPIONs to the latent form of TGF-&beta, since heat has been shown to induce release of TGF-&beta, from the latent complex. Commercially available SPIONS with high specific absorption rates (SAR) were hydrolyzed in 70% ethanol to create surface carboxylic acid conjugation sites for carbodiimide chemistry. Fourier-Transform Infra-Red (FTIR) analysis verified the conversion of maleic anhydride to maleic acid. 1-Ethyl-2-(3-dimethyulaminopropyl) carbodiimide (EDC) and N-hydroxysulfosuccinimide (Sulfo-NHS) were used to bind to the open conjugation sites of the SPION in order to graft latent TGF-&beta, onto the particles. The resulting conjugated particles were imaged with transmission electron microscopy (TEM), and the complexed particles were characterized by dynamic light scattering (DLS) and superconducting quantum interference device (SQUID) magnetometry. Enzyme-linked immunosorbent assay (ELISA) was used to assess the thermally triggered release of active TGF-&beta, from the latent complex, demonstrating that conjugation did not interfere with release. Results showed that latent TGF-&beta, was successfully conjugated to the iron oxide nanoparticles, and magnetically triggered release of active TGF-&beta, was achieved.